AGENDA

Uniform Formulary Beneficiary Advisory Panel (BAP)
For the February 2022 DoD Pharmacy and Therapeutics Committee Meetings
April 6, 2022 at 10:00 AM Eastern Daylight Saving Time

Virtual Meeting

- **Administrative Meeting: 8:00 AM – 9:45 AM Eastern Daylight Saving Time (General session starts at 10:00 AM Eastern Daylight Saving Time)**
- **Roll Call**
- **Therapeutic Class Reviews**

  Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

  The P&T Committee made recommendations for the following drugs/drug classes during the February 2022 meeting:

  - **Drug Class Reviews**
    - *Oncological Agents*
      - *Renal Cell Carcinoma (RCC)*
      - *Epidermal Growth Factor Receptor (EGFR) + Non-Small Cell Lung Cancer (NSCLC) subclass*
      - *Non-Bruton Tyrosine Kinase Inhibitors (Non-BTKIs) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) subclass*
      - *Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors for BRCA+ Cancers (PARPIs) subclass*
      - *Janus Kinase Inhibitors for Myelofibrosis subclass*
    - *Binders-Chelators-Antidotes-Overdose Agent for severe hypoglycemia – Glucagon products*

  - **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
    - *asciminib (Scemblix) – Oncologic Agent for chronic myelogenous leukemia (CML) in chronic phase (CP)*
    - *atogepant (Qulipta) – Migraine Agent for the preventative treatment of episodic migraine in adults*
    - *avacopan (Tavneos) – Hematological Agent for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA)*

- *carbidopa/levodopa (Dhivy) – Parkinson's Disease agent*
- *celecoxib oral solution (Elyxyb) –NSAID for acute migraine headache*
- *lonapegsomatropin-tcgd injection (Skytrofa) – Growth Stimulating Agent*
- *marabavir (Livtencity) – Antiviral for CMV infection/disease*
- *maralixibat (Livmarli) – Miscellaneous Metabolic agent for cholestatic pruritus in Alagille syndrome*
- *ropeginterferon alfa-2b-njft injection (Besremi) – Hematological agent for polycythemia vera*
- *topiramate oral solution (Eprontia) – Anticonvulsant-Antimania Agent for epilepsy, migraine headache, and Lennox-Gastaut syndrome*
- *varenicline nasal solution (Tyrvaya) –Dry Eye Disease Agent*
- *vosoritide injection (Voxzogo) – Miscellaneous Growth Stimulating Agent for pediatric achondroplasia*

- **Utilization Management Issues**
  - **Prior Authorization Criteria—New Manual PA Criteria**
    - *Antilipidemics-2 – fenofibrate 40 mg and 120 mg (Fenoglide)*
    - *NSAIDs – indomethacin 50 mg suppositories (Indocin)*
    - *Vitamins: Prenatal – Prenatal Multivitamins (Neonatal Plus)*
    - *Androgens-Anabolic Steroids: Intramuscular (IM) Testosterone Replacement Therapy – testosterone cypionate and testosterone enanthate*
  - **Prior Authorization Criteria—Updated PA Criteria for New FDA-Approved Indications, National Comprehensive Cancer Network Guideline Updates, or Age Ranges**
    - *Respiratory Interleukins*: *dupilumab (Dupixent)*
    - *Hepatitis C Agent –Direct Acting Agents*: *elbasvir/grazoprevir (Zepatier)*
    - *Atypical Antipsychotic Agents*
      - *brexpiprazole (Rexulti)*
      - *lumateperone (Caplyta)*
    - *Targeted Immunomodulatory Biologics (TIBs)*
      - *risankizumab-rzaa (Skyrizi)*
      - *secukinumab (Cosentyx)*

- *tofacitinib (Xeljanz/Xeljanz XR*
- *upadacitinib (Rinvoq ER)*

- **Prior Authorization Criteria—Removal of Indication**
  - *Oncological Agents: Non-Bruton Tyrosine Kinase Inhibitors (Non-BTKIs) for Chronic Lymphocytic Leukemia – duvelisib (Copiktra)*

➢ **Removal of Brand Over Generic Authorization**

- *Pulmonary Is: Inhaled Corticosteroid/Long Acting Beta Agonist Inhalers: fluticasone/salmeterol dry powder inhaler (Advair Diskus)*

➢ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.